Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
TEL AVIV, Israel, March 07, 2016 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will announce financial results for the fourth quarter and fiscal year ended December 31, 2015 and host a conference call and live audio webcast on Tuesday, March 29, at 8:30 a.m. Eastern Time.
| Tuesday, March 29, 2016 @ 8:30am Eastern Time | |
| Domestic: | 888-428-9480 |
| International: | 719-457-2648 |
| Conference ID: | 3465224 |
| Webcast: | http://edge.media-server.com/m/p/a4mzgp3s |
| Replays, available through April 6, 2016 | |
| Toll Free: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 3465224 |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, VB-111, is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. It has demonstrated safety in >170 cancer patients and efficacy signals in an `all comers` Ph1 trial as well as in three tumor-specific Ph2 studies. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is currently being studied in a Ph3 pivotal trial for Recurrent Glioblastoma (rGBM); the trial is being conducted under an FDA Special Protocol Assessment (SPA), fast track and Orphan designation.
INVESTOR CONTACT: Michael Rice, Founding Partner LifeSci Advisors, LLC 646-597-6979
